OTCMKTS:ARTH Arch Therapeutics (ARTH) Stock Price, News & Analysis $0.16 0.00 (0.00%) As of 11/20/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartSEC Filings About Arch Therapeutics Stock (OTCMKTS:ARTH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Arch Therapeutics alerts:Sign Up Key Stats Today's Range$0.16▼$0.1650-Day Range$0.16▼$0.1652-Week Range$0.16▼$1.57VolumeN/AAverage Volume4,068 shsMarket Capitalization$762.51 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Arch Therapeutics is a medical device company developing products based on its proprietary self-assembling peptide technology. The technology is designed to form a biodegradable nanofiber barrier at a wound site, helping control bleeding and support wound closure. The company’s product portfolio includes the AC5 Advanced Wound System, developed for use in managing acute and chronic wounds, and the AC5 Surgical Hemostatic Device, intended to help control bleeding during surgical procedures. Arch Therapeutics focuses on developing and bringing these products to market, with its activities centered primarily on the United States. Its approach is intended to provide a physical barrier at the treatment site rather than relying on conventional topical agents.AI Generated. May Contain Errors. Read More Receive ARTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARTH Stock News HeadlinesArch Therapeutics Inc. (ARTH) Product Pipeline Analysis, 2025 UpdateAugust 9, 2025 | finance.yahoo.comArch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)October 1, 2024 | globenewswire.comToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.November 21 at 1:00 AM | Behind the Markets (Ad)Chicago biotech-focused VC firm Arch Venture Partners closes $3 billion fundSeptember 27, 2024 | bizjournals.comArch Therapeutics, Inc. (ARTH)August 21, 2024 | finance.yahoo.comArch Biopartners' Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug ToxinsAugust 2, 2024 | tmcnet.comArch Therapeutics Secures $750K Prepayment for StockFebruary 8, 2024 | msn.comArch Therapeutics Inc ARTHJanuary 6, 2024 | morningstar.comMSee More Headlines ARTH Stock Analysis - Frequently Asked Questions How have ARTH shares performed this year? Arch Therapeutics' stock was trading at $0.1608 on May 30, 2026. Since then, ARTH shares have increased by 0.0% and is now trading at $0.1608. How were Arch Therapeutics' earnings last quarter? Arch Therapeutics, Inc. (OTCMKTS:ARTH) issued its quarterly earnings data on Thursday, July, 23rd. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $0.01. How do I buy shares of Arch Therapeutics? Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arch Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arch Therapeutics investors own include Aptose Biosciences (APTO), Aurinia Pharmaceuticals (AUPH), SCYNEXIS (SCYX), Actinium Pharmaceuticals (ATNM), Bellerophon Therapeutics (BLPH), AT&T (T) and Sorrento Therapeutics (SRNE). Company Calendar Today11/21/2026Fiscal Year End9/30/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolOTCMKTS:ARTH Previous SymbolNASDAQ:ARTH CIK1537561 Webwww.archtherapeutics.com Phone(617) 431-2313FaxN/AEmployees10Year Founded2006Profitability EPS (Trailing Twelve Months)($2.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.98 million Net Margins-8,257.70% Pretax Margin-8,257.70% Return on EquityN/A Return on Assets-730.22% Debt Debt-to-Equity RatioN/A Current Ratio0.10 Quick Ratio0.01 Sales & Book Value Annual Sales$80 thousand Price / Sales9.53 Cash FlowN/A Price / Cash FlowN/A Book Value($2.43) per share Price / Book-0.07Miscellaneous Outstanding Shares4,742,000Free Float4,529,000Market Cap$762.51 thousand OptionableNot Optionable Beta4.02 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:ARTH) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arch Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arch Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.